Recommendation informed by Phase 3 findings showing a booster increased protection to 94 percent against moderate to severe/critical COVID-19 in the U.S. Johnson & Johnson COVID-19 vaccine, when given as a booster or primary dose, was generally well-tolerated FDA to decide whether to authorize a booster dose in the coming days
